鞘内巴氯芬治疗痉挛的并发症:由 170 人组成的单中心队列。

IF 3.9 3区 医学 Q1 REHABILITATION Annals of Physical and Rehabilitation Medicine Pub Date : 2025-01-10 DOI:10.1016/j.rehab.2024.101919
Matthieu Gahier, Thomas Hirardot, Kévin Buffenoir, Brigitte Perrouin-Verbe, Raphaël Gross
{"title":"鞘内巴氯芬治疗痉挛的并发症:由 170 人组成的单中心队列。","authors":"Matthieu Gahier, Thomas Hirardot, Kévin Buffenoir, Brigitte Perrouin-Verbe, Raphaël Gross","doi":"10.1016/j.rehab.2024.101919","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intrathecal baclofen (ITB) therapy effectively reduces severe spasticity but is associated with complications that can be serious. The evolution of these complications over time and their predictive factors are not well known.</p><p><strong>Objectives: </strong>The primary aim was to describe the incidence of ITB complications in adults with neurological disorders and disabling spasticity. The secondary aims were to describe the complications and the time-course of their incidence, to identify factors associated with complications, and to evaluate ITB effectiveness.</p><p><strong>Method: </strong>We conducted a retrospective, single-centre, longitudinal observational study of data from people implanted with an ITB pump between 1995 and 2023. We calculated the incidence of complications overall and per category, and their evolution over the study period. Factors associated with complications were searched among demographic, clinical, device-related, and ITB dose characteristics. Effectiveness of ITB therapy was assessed using a goal-achievement scale.</p><p><strong>Results: </strong>Data from 170 individuals were included (1577 years of ITB therapy); 198 complications were reported. Complication incidence was 0.13 events per pump-year and rate was 0.63 events per implantation. 49 % of complications were device related, 31 % procedure related and 20 % drug related. Surgical intervention was required for 63 % of complications. The main risk factors were walking capacity with odds ratio (OR) 3.12 (95 % CI 1.14 to 9.10, P = 0.030), and pre-Ascenda catheters with OR 3.36 (95 % CI 1.28 to 9.10, P = 0.014). Synchromed II pumps were associated with a higher risk of procedure-related complications: OR 3.41 (95 % CI 1.14 to 12.12, P = 0.039). Complication incidence decreased continuously during the study period, mainly because of a reduction in the number of device-related complications. Goals were partially achieved in 51 % of participants and achieved in 37 %.</p><p><strong>Conclusions: </strong>The incidence of complications associated with ITB therapy was high, and complications were mostly serious (requiring hospitalisation and/or life threatening). We recommend thorough examination of the benefits and risks of ITB therapy for each individual and systematic screening for dysfunctions at follow-up visits.</p>","PeriodicalId":56030,"journal":{"name":"Annals of Physical and Rehabilitation Medicine","volume":"68 3","pages":"101919"},"PeriodicalIF":3.9000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Complications of intrathecal baclofen therapy for spasticity: A single-centre cohort of 170 individuals.\",\"authors\":\"Matthieu Gahier, Thomas Hirardot, Kévin Buffenoir, Brigitte Perrouin-Verbe, Raphaël Gross\",\"doi\":\"10.1016/j.rehab.2024.101919\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Intrathecal baclofen (ITB) therapy effectively reduces severe spasticity but is associated with complications that can be serious. The evolution of these complications over time and their predictive factors are not well known.</p><p><strong>Objectives: </strong>The primary aim was to describe the incidence of ITB complications in adults with neurological disorders and disabling spasticity. The secondary aims were to describe the complications and the time-course of their incidence, to identify factors associated with complications, and to evaluate ITB effectiveness.</p><p><strong>Method: </strong>We conducted a retrospective, single-centre, longitudinal observational study of data from people implanted with an ITB pump between 1995 and 2023. We calculated the incidence of complications overall and per category, and their evolution over the study period. Factors associated with complications were searched among demographic, clinical, device-related, and ITB dose characteristics. Effectiveness of ITB therapy was assessed using a goal-achievement scale.</p><p><strong>Results: </strong>Data from 170 individuals were included (1577 years of ITB therapy); 198 complications were reported. Complication incidence was 0.13 events per pump-year and rate was 0.63 events per implantation. 49 % of complications were device related, 31 % procedure related and 20 % drug related. Surgical intervention was required for 63 % of complications. The main risk factors were walking capacity with odds ratio (OR) 3.12 (95 % CI 1.14 to 9.10, P = 0.030), and pre-Ascenda catheters with OR 3.36 (95 % CI 1.28 to 9.10, P = 0.014). Synchromed II pumps were associated with a higher risk of procedure-related complications: OR 3.41 (95 % CI 1.14 to 12.12, P = 0.039). Complication incidence decreased continuously during the study period, mainly because of a reduction in the number of device-related complications. Goals were partially achieved in 51 % of participants and achieved in 37 %.</p><p><strong>Conclusions: </strong>The incidence of complications associated with ITB therapy was high, and complications were mostly serious (requiring hospitalisation and/or life threatening). We recommend thorough examination of the benefits and risks of ITB therapy for each individual and systematic screening for dysfunctions at follow-up visits.</p>\",\"PeriodicalId\":56030,\"journal\":{\"name\":\"Annals of Physical and Rehabilitation Medicine\",\"volume\":\"68 3\",\"pages\":\"101919\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-01-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Physical and Rehabilitation Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.rehab.2024.101919\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"REHABILITATION\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Physical and Rehabilitation Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.rehab.2024.101919","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"REHABILITATION","Score":null,"Total":0}
引用次数: 0

摘要

背景:鞘内巴氯芬(ITB)治疗可有效减少严重痉挛,但可能伴有严重的并发症。这些并发症随时间的演变及其预测因素尚不清楚。目的:主要目的是描述患有神经系统疾病和致残性痉挛的成人ITB并发症的发生率。次要目的是描述并发症及其发生的时间过程,确定与并发症相关的因素,并评估ITB的有效性。方法:我们对1995年至2023年间植入ITB泵的患者进行了一项回顾性、单中心、纵向观察研究。我们计算了并发症的总体发生率和每个类别,以及它们在研究期间的演变。在人口统计学、临床、器械相关和ITB剂量特征中搜索与并发症相关的因素。使用目标-成就量表评估ITB治疗的有效性。结果:纳入了170名患者的数据(1577年的ITB治疗);共报告并发症198例。并发症发生率为0.13次/泵年,发生率为0.63次/泵年。49%的并发症与器械有关,31%与手术有关,20%与药物有关。63%的并发症需要手术干预。主要危险因素为行走能力,比值比(OR)为3.12 (95% CI 1.14 ~ 9.10, P = 0.030),上升前置管的比值比为3.36 (95% CI 1.28 ~ 9.10, P = 0.014)。同步II型泵与手术相关并发症的高风险相关:OR为3.41 (95% CI 1.14至12.12,P = 0.039)。在研究期间,并发症的发生率持续下降,主要是因为器械相关并发症的数量减少。51%的参与者部分实现了目标,37%的参与者实现了目标。结论:与ITB治疗相关的并发症发生率高,且并发症大多严重(需要住院和/或危及生命)。我们建议对每个个体进行全面的ITB治疗的益处和风险检查,并在随访时系统地筛查功能障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Complications of intrathecal baclofen therapy for spasticity: A single-centre cohort of 170 individuals.

Background: Intrathecal baclofen (ITB) therapy effectively reduces severe spasticity but is associated with complications that can be serious. The evolution of these complications over time and their predictive factors are not well known.

Objectives: The primary aim was to describe the incidence of ITB complications in adults with neurological disorders and disabling spasticity. The secondary aims were to describe the complications and the time-course of their incidence, to identify factors associated with complications, and to evaluate ITB effectiveness.

Method: We conducted a retrospective, single-centre, longitudinal observational study of data from people implanted with an ITB pump between 1995 and 2023. We calculated the incidence of complications overall and per category, and their evolution over the study period. Factors associated with complications were searched among demographic, clinical, device-related, and ITB dose characteristics. Effectiveness of ITB therapy was assessed using a goal-achievement scale.

Results: Data from 170 individuals were included (1577 years of ITB therapy); 198 complications were reported. Complication incidence was 0.13 events per pump-year and rate was 0.63 events per implantation. 49 % of complications were device related, 31 % procedure related and 20 % drug related. Surgical intervention was required for 63 % of complications. The main risk factors were walking capacity with odds ratio (OR) 3.12 (95 % CI 1.14 to 9.10, P = 0.030), and pre-Ascenda catheters with OR 3.36 (95 % CI 1.28 to 9.10, P = 0.014). Synchromed II pumps were associated with a higher risk of procedure-related complications: OR 3.41 (95 % CI 1.14 to 12.12, P = 0.039). Complication incidence decreased continuously during the study period, mainly because of a reduction in the number of device-related complications. Goals were partially achieved in 51 % of participants and achieved in 37 %.

Conclusions: The incidence of complications associated with ITB therapy was high, and complications were mostly serious (requiring hospitalisation and/or life threatening). We recommend thorough examination of the benefits and risks of ITB therapy for each individual and systematic screening for dysfunctions at follow-up visits.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.80
自引率
4.30%
发文量
136
审稿时长
34 days
期刊介绍: Annals of Physical and Rehabilitation Medicine covers all areas of Rehabilitation and Physical Medicine; such as: methods of evaluation of motor, sensory, cognitive and visceral impairments; acute and chronic musculoskeletal disorders and pain; disabilities in adult and children ; processes of rehabilitation in orthopaedic, rhumatological, neurological, cardiovascular, pulmonary and urological diseases.
期刊最新文献
Return to sport after anterior cruciate ligament reconstruction - prognostic factors and prognostic models: A systematic review. “From pain to neglect behavior of peripheral origin” Diffusion tensor imaging reveals Papez circuit lesions in severe traumatic brain injury with memory disorder. Simulated breathing in virtual reality does not affect perceived effort during the physical rehabilitation of people with long COVID Intensive interdisciplinary specialized rehabilitation or regular physiotherapy for multiple sclerosis? A randomised controlled trial with economic evaluation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1